Actually, it would be interesting to carry out a PRS with PCSK9 variants and CIMT in several populations with distinct background admixture and diverse clinical outcomes, including intermediate phenotypes, which could provide us additional knowledge to link the PRS for cardiovascular diseases and could be implemented in clinical care as a potential marker with an approach of translational risk prediction. Here, PCSK9 is linked to cardiovascular disorder.